Nuclera Overview
Pro stress-test →Nuclera is a biotechnology company accelerating drug discovery by providing rapid, easy access to functional proteins through its benchtop eProtein Discovery™ System. The platform delivers assay-ready proteins, including challenging membrane proteins, in as little as 48 hours through multiplex screening of constructs, tags, and conditions, addressing a critical bottleneck in biologics research and drug development.
Strategic Profile
Pro stress-test →Nuclera is moving into AI-enabled protein engineering, addressing a critical industry need for scalable, standardized, and high-quality datasets that can be used to power next-generation AI models. The company has secured significant funding to enable broad commercialization, expanded their leadership team to support scale-up, and continues to drive advancements in drug discovery, proteomics, and experimental automation.
Competitive Landscape
Pro stress-test →Nuclera competes in the protein engineering and synthetic biology tools space against academic platforms and automation vendors. Direct competitors include benchtop and cloud-based protein design/expression platforms serving the same pharma R&D and academic research customer base. The company's differentiation lies in speed-to-protein (48 hours), multiplex screening, and integration with AI/ML datasets for next-generation therapeutics.
Industry Context
Nuclera operates in Protein engineering platforms.
Key facts
Founded: 2016 · Headquarters: Cambridge, UK and Boston, MA · Employees: Not available · Revenue: Not publicly available